Well, when they finally do isolate some promising compounds, which I do believe exist then they can file an IND application. This will take a lot of preparation and will take some time and a lot money to do. Then if they get approval then they can start doing preclinical safety testing. Then hopefully they will get approval to start phase 1 trials. I would like to point out that it took over 2 years to get approval for HemaXellerate ater getting IND approval. In my opinion NR2F6 is going to be a lot more complicated a costly to develop. Unfortunately Koos's track record with following through with all this is shaky at best. He's pretty good at filing patents and writing PRs and that's about it. Dealing with the FDA? Not so much. Orphan drug status for HemaXellerate? "crickets".
Basically, for those that are looking for a quick and big payoff you are going to be disappointed. The pot of gold at the end of this is going to be pretty small. Big pharma is not as free with their money as they once were. They are waiting now for small companies to take their new trials to phase 2 and beyond before jumping in and taking over and that is many many years away at this point.
News 
Market Data 
Discover 
